These 3 Stocks Surged During Thursday's Sell-Off

Stocks saw rather large declines on Thursday, driven by concerns surrounding possible tariff-related retaliation from China against U.S. giants such as Boeing (NYSE:BA) , while Facebook’s (NASDAQ:FB) data breach woes escalated. These bellwethers helped contribute to a nearly 2.5% decline in the S&P 500 index as investors continue to assess the cost of rising interest rates and possible trade wars.

On top of the S&P 500’s decline, the Dow Jones Industrial average sunk nearly 3%—or 724.42 points.

Nevertheless, several companies were able to buck the broader market-wide trends to post solid gains on Thursday.

Let’s see why a few stocks were able to finish in the green.

1. Five Below (NASDAQ:FIVE)

Shares of this discount retailer surged 4.2% after posting better-than-expected Q4 results on both the top and bottom lines. Five Below also provided upbeat guidance, which might be why its stock price inched closer to its 52-week high on Thursday. The company now expects to post revenues between $290 million and $294 million in the current quarter, which beats our current estimate of $286.3 million.

Five Below’s stock price had already skyrocketed nearly 76% before Thursday’s climb as investors continue to love strong discount retail performers. The company is currently sporting a Zacks Rank #3 (Hold), but that could change if analysts update their estimates based on Five Below’s new outlook.

2. Ares Capital Corporation (NASDAQ:ARCC)

This financial services company saw its stock price climb nearly 4% to close within $2 of its 52-week high. Today’s big surge saw the company’s volume skyrocket to 8.8 million, far above its average volume of 2.1 million.

Looking ahead to the first quarter, Ares’ sales are projected to climb 11.4%, while its earnings expected to jump by 15.6% to reach $0.37 per share. Ares is currently a Zacks Rank #3 (Hold) and sports a “B” grade for Value.

3. Omeros Corporation (NASDAQ:OMER)

Shares of this commercial-stage biotech firm soared over 35% after the U.S. government’s new $1.3 trillion spending package passed on Thursday. Investors had previously fled the stock after its cataract surgery drug lost its pass-through status for Medicare and Medicaid Services on January 1. The new bill will reportedly grant the drug pass-through status once again.

Omeros’ volume skyrocketed far above its average volume of 1 million to 15.3 million. It is unclear if Thursday’s surge will last, but the company is expected to see its sales climb by 15.4% this quarter and 49% for the full year.

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>